SML2161

STA-21

≥95% (HPLC)

• Sinónimos: (±)-Deoxytetrangomycin, (±)-Ochromycinone, 3,4-Dihydro-8-hydroxy-3-methylbenz[a]anthracene-1,7,12(2H)-trione, NSC 628869, STA 21, STA21
• Fórmula empírica (notación de Hill): C₁₉H₁₄O₄
• Número de CAS: 111540-00-2
• Peso molecular: 306.31
• MDL number: MFCD16883374
• UNSPSC Code: 12352200
• NACRES: NA.77

Propiedades

• assay: ≥95% (HPLC)
• form: powder
• color: yellow to brown
• solubility: DMSO: 2 mg/mL, clear
• storage temp.: −20°C
• SMILES string: CC1CC(C(C(C(C(C=CC=C2O)=C2C3=O)=O)=C3C=C4)=C4C1)=O

Descripción

Application

STA-21 has been used as a signal transducer and activator of transcription 3 (STAT3) inhibitor to study its effects on glioblastoma and primary glioblastoma cells. It has also been used as a STAT3 dimerization inhibitor to study its effects on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) production in human lung cancer cell line.

Biochem/physiol Actions

STA-21 is a STAT3 inhibitor that reduces the constitutively high STAT3 transcriptional activity in Caov-3 and MDA-MB-435s cultures (by 9.125- and 5.765-fold, respectively, post 48-hr 20 μM treatment) by disrupting STAT3 homodimerization, an essential process for STAT3 nuclear localization and DNA-binding activity. STA-21 selectively inhibits the growth and survival of breast carcinoma cells with constitutive Stat3 signaling (26%, 25%, 56% apoptotic cells, respectively, in MDA-MB-231, MDA-MB-435s, and MDA-MB-468 cultures, respectively, post 48-hr 20 μM treatment) but not those without (<10% apoptosis in MCF7, MDA-MB-453, HSF cultures post 48-hr 20 μM treatmen). STA-21 is reported to alleviate autoimmune inflammation in a murine model of rheumatoid arthritis (RA; 0.5 mg/kg; 3X i.p./week) and reduce airway inflammation in allergic mice with psoriatic inflammation (20 μg/mouse/day topically) in vivo.

Información de seguridad

• Storage Class: 11 - Combustible Solids
• wgk_germany: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable